FDA approves Pfizer's supplemental new drug application for CIBINQO
Label expansion for CIBINQO provides new systemic oral option for adolescents (12 to <18 years) with moderate-to-severe atopic dermatitis
Label expansion for CIBINQO provides new systemic oral option for adolescents (12 to <18 years) with moderate-to-severe atopic dermatitis
CHMP recommendation is based on Phase III data, which demonstrated that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel significantly reduced the risk of death by 32.5%
Approval marks fifth indication for KEYTRUDA-based regimens in NSCLC and 34th indication for KEYTRUDA in the US
SEZABY is a benzyl alcohol-free and propylene glycol-free formulation of phenobarbital sodium powder for injection
The supplemental New Drug Application is based on results from the landmark EMPA-KIDNEY phase III trial
AI-based medical imaging equipment firm Lunit has signed a contract to supply AI-based breast cancer screening solution “Lunit Insight MMG”
Sacu V is priced at Rs. 19 per tablet for a dose of 50 mg (sacubitril 24 mg + valsartan 26 mg)
India's G20 Presidency will focus on three main priorities: Health Emergencies Prevention, Preparedness and Response (One Health & AMR); Access and Availability to Affordable Medical Countermeasures (Vaccines, Therapeutics, and Diagnostics); and Digital Health
This will give either party customers access enzyme expertise and assets, resulting in cost-effective, green processing for API manufacturing.
The goal of Dozee’s partnership with BII is to improve access to healthcare across India and alleviate the workload of healthcare workers, reduce nurse burnout and fatigue in hospital wards
Subscribe To Our Newsletter & Stay Updated